Medicus Pharma Company Insiders
| MDCX Stock | USD 1.95 0.14 6.70% |
Medicus Pharma employs about 10 people. The company is managed by 10 executives with a total tenure of roughly 0 years, averaging almost 0.0 years of service per executive, having 1.0 employees per reported executive. Break down of Medicus Pharma's management performance can provide insight into the company performance.
| MBA MD Chairman CEO Chairman |
| Carolyn Bonner President President |
Medicus Pharma Management Team Effectiveness
The company has return on total asset (ROA) of (1.7069) % which means that it has lost $1.7069 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (26.6081) %, meaning that it created substantial loss on money invested by shareholders. Medicus Pharma's management efficiency ratios could be used to measure how well Medicus Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.97 in 2025. Return On Capital Employed is likely to drop to -3.51 in 2025. At this time, Medicus Pharma's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 5.6 M in 2025, whereas Net Tangible Assets are likely to drop (75.7 K) in 2025.Common Stock Shares Outstanding is likely to drop to about 9.9 M in 2025. Net Loss is likely to drop to about (167.7 K) in 2025
Medicus Pharma Workforce Comparison
Medicus Pharma Ltd is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 669. Medicus Pharma adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Medicus Pharma Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Medicus Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Medicus Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Medicus Pharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Quinlan James P. over three months ago Disposition of 20000 shares by Quinlan James P. of Medicus Pharma at 2.75 subject to Rule 16b-3 | ||
Kaiser Larry over three months ago Insider Trading | ||
Velocity Fund Partners, Lp over six months ago Insider Trading | ||
Velocity Fund Partners, Lp over six months ago Disposition of 75000 shares by Velocity Fund Partners, Lp of Medicus Pharma at 7.7192 subject to Rule 16b-3 | ||
Kaiser Larry over six months ago Insider Trading | ||
Ashton William over six months ago Insider Trading |
Medicus Pharma Notable Stakeholders
A Medicus Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Medicus Pharma often face trade-offs trying to please all of them. Medicus Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Medicus Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| MBA MD | CEO Chairman | Profile | |
| Carolyn Bonner | President | Profile | |
| Viktoria Slepeniuk | Senior Relations | Profile | |
| Brennan FACS | Chief Program | Profile | |
| Andrew Smith | Chief Officer | Profile | |
| James CPA | Chief Officer | Profile | |
| Maryann Adesso | Chief Secretary | Profile | |
| Faisal MD | Chief Officer | Profile | |
| Viktoriia Slepeniuk | Senior Relations | Profile | |
| Anna JD | Senior Relations | Profile |
About Medicus Pharma Management Performance
The success or failure of an entity such as Medicus Pharma often depends on how effective the management is. Medicus Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Medicus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Medicus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.88) | (1.97) | |
| Return On Capital Employed | (3.35) | (3.51) | |
| Return On Assets | (1.88) | (1.97) | |
| Return On Equity | (3.39) | (3.56) |
Please note, the imprecision that can be found in Medicus Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Medicus Pharma Ltd. Check Medicus Pharma's Beneish M Score to see the likelihood of Medicus Pharma's management manipulating its earnings.
Medicus Pharma Workforce Analysis
Traditionally, organizations such as Medicus Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Medicus Pharma within its industry.Medicus Pharma Manpower Efficiency
Return on Medicus Pharma Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.1M | |
| Net Loss Per Executive | 1.1M | |
| Working Capital Per Employee | 307.2K | |
| Working Capital Per Executive | 307.2K |
Additional Tools for Medicus OTC BB Equity Analysis
When running Medicus Pharma's price analysis, check to measure Medicus Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medicus Pharma is operating at the current time. Most of Medicus Pharma's value examination focuses on studying past and present price action to predict the probability of Medicus Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medicus Pharma's price. Additionally, you may evaluate how the addition of Medicus Pharma to your portfolios can decrease your overall portfolio volatility.